<DOC>
	<DOC>NCT01184287</DOC>
	<brief_summary>The purpose of the trial is to determine the rate of improvement in objective tumor response, following the addition of ranpirnase to ongoing pemetrexed—carboplatin chemotherapy, for patients with SD or PR following 2 cycles of doublet chemotherapy.</brief_summary>
	<brief_title>A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ranpirnase</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Age greater than 18 years ECOG less than 2 Estimated survival of greater than 12 weeks Prior systemic chemotherapy for locally advanced or metastatic NSCLC Use of any investigational agent within 28 days prior to registration Known hypersensitivity to any of the study drugs Brain metastases or leptomeningeal disease History of prior malignancy within the past three years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Non Small Cell Lung Cancer, NSCLC, Lung Cancer</keyword>
	<keyword>Previously untreated Non-Squamous, Non-Small Cell Lung Cancer</keyword>
</DOC>